199 related articles for article (PubMed ID: 33719084)
1. Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects.
Katragadda S; Neelakantan S; Diao L; Wong N
J Clin Pharmacol; 2021 Jul; 61(7):889-900. PubMed ID: 33719084
[TBL] [Abstract][Full Text] [Related]
2. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
Nestorov I; Neelakantan S; Ludden TM; Li S; Jiang H; Rogge M
Clin Pharmacol Drug Dev; 2015; 4(3):163-74. PubMed ID: 27140796
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
[TBL] [Abstract][Full Text] [Related]
5. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
Powell JS; Josephson NC; Quon D; Ragni MV; Cheng G; Li E; Jiang H; Li L; Dumont JA; Goyal J; Zhang X; Sommer J; McCue J; Barbetti M; Luk A; Pierce GF
Blood; 2012 Mar; 119(13):3031-7. PubMed ID: 22223821
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
[TBL] [Abstract][Full Text] [Related]
7. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
[TBL] [Abstract][Full Text] [Related]
9. A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients.
Bukkems LH; Heijdra JM; Mathias M; Collins PW; Hay CRM; Tait RC; Mangles S; Myers B; Evans G; Bailiff B; Curry N; Payne J; Austin S; Goedhart TMHJ; Leebeek FWG; Meijer K; Fijnvandraat K; Chowdary P; Mathôt RAA; Cnossen MH;
Thromb Haemost; 2020 May; 120(5):747-757. PubMed ID: 32369846
[TBL] [Abstract][Full Text] [Related]
10. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
Miners AH; Krishnan S; Pasi KJ
J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
[TBL] [Abstract][Full Text] [Related]
11. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
[TBL] [Abstract][Full Text] [Related]
13. Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Shah A; Solms A; Wiegmann S; Ahsman M; Berntorp E; Tiede A; Iorio A; Mancuso ME; Zhivkov T; Lissitchkov T
Ann Hematol; 2019 Sep; 98(9):2035-2044. PubMed ID: 31236667
[TBL] [Abstract][Full Text] [Related]
14. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A.
Mahlangu JN; Ragni M; Gupta N; Rangarajan S; Klamroth R; Oldenburg J; Nogami K; Young G; Cristiano LM; Dong Y; Allen G; Pierce GF; Robinson B
Thromb Haemost; 2016 Jul; 116(1):1-8. PubMed ID: 26962852
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.
Peters RT; Toby G; Lu Q; Liu T; Kulman JD; Low SC; Bitonti AJ; Pierce GF
J Thromb Haemost; 2013 Jan; 11(1):132-41. PubMed ID: 23205847
[TBL] [Abstract][Full Text] [Related]
16. The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein.
Leksa NC; Chiu PL; Bou-Assaf GM; Quan C; Liu Z; Goodman AB; Chambers MG; Tsutakawa SE; Hammel M; Peters RT; Walz T; Kulman JD
J Thromb Haemost; 2017 Jun; 15(6):1167-1179. PubMed ID: 28397397
[TBL] [Abstract][Full Text] [Related]
17. Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States.
McMullen S; Buckley B; Hall E; Kendter J; Johnston K
Value Health; 2017 Jan; 20(1):93-99. PubMed ID: 28212975
[TBL] [Abstract][Full Text] [Related]
18. A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.
Buyue Y; Liu T; Kulman JD; Toby GG; Kamphaus GD; Patarroyo-White S; Lu Q; Reidy TJ; Mei B; Jiang H; Pierce GF; Sommer JM; Peters RT
PLoS One; 2014; 9(11):e113600. PubMed ID: 25415306
[TBL] [Abstract][Full Text] [Related]
19. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
Simpson ML; Desai V; Maro GS; Yan S
J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
[TBL] [Abstract][Full Text] [Related]
20. [Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
Sattler L; Raissi A; Fornoff D; Gérout AC; Feugeas O; Grunebaum L; Desprez D
Ann Biol Clin (Paris); 2020 Feb; 78(1):35-46. PubMed ID: 32108578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]